<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2022-16-23-42-48</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-7291</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕВРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROLOGY</subject></subj-group></article-categories><title-group><article-title>Опыт применения дипиридамола во вторичной профилактике ишемического инсульта</article-title><trans-title-group xml:lang="en"><trans-title>Experience of the use of dipyridamole for secondary prevention of ischemic stroke</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0425-3481</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рахматуллина</surname><given-names>Э. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Rakhmatullina</surname><given-names>E. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рахматуллина Эльза Фагимовна - кандидат медицинских наук, доцент кафедры неврологии.</p><p>420012, Казань, ул. Муштари, д. 11</p></bio><bio xml:lang="en"><p>Elza F. Rakhmatullina - Cand. Sci. (Med.), Associate Professor of the Department of Neurology, Kazan State Medical Academy – a branch of the Federal  State  Budgetary Educational  Institution  of Additional Professional  Education “Russian Medical Academy of Continuing  Professional Education.</p><p>36, Mushtari St., Kazan, 420012</p></bio><email xlink:type="simple">elsa2109@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2707-5008</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кочергина</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kochergina</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кочергина Ольга Сергеевна - кандидат медицинских наук, доцент кафедры неврологии.</p><p>420012, Казань, ул. Муштари, д. 11</p></bio><bio xml:lang="en"><p>Olga S. Kochergina - Cand. Sci. (Med.), Associate Professor  of the  Department of Neurology, Kazan State  Medical Academy – a branch  of the Federal  State  Budgetary Educational  Institution  of Additional Professional  Education “Russian Medical Academy of Continuing  Professional Education.</p><p>36, Mushtari St., Kazan, 420012</p></bio><email xlink:type="simple">yukon0702@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6883-7649</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хайбуллина</surname><given-names>Д. Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Khaibullina</surname><given-names>D. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хайбуллина Дина Хамитовна – кандидат медицинских наук, доцент кафедры неврологии.</p><p>420012, Казань, ул. Муштари, д. 11</p></bio><bio xml:lang="en"><p>Dina K. Khaibullina - Cand. Sci. (Med.), Associate Professor  of the  Department of Neurology, Kazan State  Medical Academy – a branch  of the Federal  State  Budgetary Educational  Institution  of Additional Professional  Education “Russian Medical Academy of Continuing  Professional Education.</p><p>36, Mushtari St., Kazan, 420012</p></bio><email xlink:type="simple">dina.khaibullina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Казанская государственная медицинская академия – филиал Российской медицинской академии непрерывного профессионального образования</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical Academy – a branch of the Russian Medical Academy of Continuing Professional  Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>16</day><month>01</month><year>2023</year></pub-date><volume>0</volume><issue>23</issue><fpage>42</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рахматуллина Э.Ф., Кочергина О.С., Хайбуллина Д.Х., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Рахматуллина Э.Ф., Кочергина О.С., Хайбуллина Д.Х.</copyright-holder><copyright-holder xml:lang="en">Rakhmatullina E.F., Kochergina O.S., Khaibullina D.K.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/7291">https://www.med-sovet.pro/jour/article/view/7291</self-uri><abstract><p>Острое нарушение мозгового кровообращения (ОНМК) является важной медико-социальной  проблемой, что связано с высокой заболеваемостью, смертностью и частой инвалидизацией. Существующая на сегодняшний день система оказания специализированной медицинской помощи больным ОНМК показала свою эффективность, что подтверждается снижением госпитальной летальности и увеличением  числа пациентов, возвратившихся  к труду. Однако заболеваемость инсультом остается по-прежнему высокой, что связано также с пандемией COVID-19. Каждый третий пациент с COVID-19 имел неврологическую симптоматику, а при патоморфологическом  исследовании мозга умерших у каждого пятого выявлялись признаки гипоксической энцефалопатии. В связи с тем, что при COVID-19 высока вероятность развития ишемического инсульта (ИИ), необходимо своевременно выявить и скорректировать  следующие факторы, способствующие возникновению  инсульта при COVID-19: кардиоваскулярные  заболевания, сахарный диабет, артериальная  гипертензия, атеросклероз. Непосредственное поражение вирусом приводит к системной воспалительной гиперактивности с протромботическим  состоянием, вторичным по отношению к дефициту протеина C и S. Важной проблемой является как профилактика первого, так и повторного инсульта, не зависимо от этиологии. В основе вторичной профилактики лежит коррекция факторов риска, а также разработка индивидуальной программы с проведением антигипертензивной, гиполипидемической терапии. Ведущим же направлением вторичной профилактики ИИ является антиагрегантная  терапия, которая уменьшает риск развития  острых сосудистых эпизодов  на 25%. В целях вторичной профилактики ИИ используются ацетилсалициловая кислота, дипиридамол, клопидогрел. В обсуждаемом клиническом наблюдении у пациента на фоне стенозирующего процесса в общей сонной артерии, гипертонической болезни и перенесенной коронавирусной  инфекции развились повторные эпизоды транзиторной ишемической атаки. Учитывая, что наибольший  риск повторного  инсульта связан  с атеросклерозом, который может осложниться тромбообразованием, для вторичной профилактики были выбраны курантил и ацетилсалициловая  кислота. Катамнестическое  наблюдение  показало правильность выбранной тактики.</p></abstract><trans-abstract xml:lang="en"><p>Acute cerebrovascular accident  (ACV) is an important medical and social problem, which is associated with high morbidity, mortality and frequent  disability. The current  system  for providing  specialized  medical  care to patients with stroke  has shown  its effectiveness, as evidenced by a decrease in hospital  mortality  and  an increase  in the  number  of patients returning  to work. However, the incidence  of stroke remains  high, which is also associated with the COVID-19 pandemic. Every third patient  with COVID-19 had neurological symptoms, and a pathomorphological study of the  brain of the  deceased showed  signs of hypoxic encephalopathy in every fifth. Due to the fact that with COVID-19 there  is a high probability of developing ischemic stroke (IS), it is necessary  to promptly identify and correct  the  following  factors  that  contribute to the  occurrence  of stroke  with COVID-19: cardiovascular  diseases, diabetes mellitus, arterial  hypertension, atherosclerosis. Direct exposure  to the virus results  in systemic inflammatory  hyperactivity  with a prothrombotic state  secondary  to protein  C and S deficiency. An important problem  is both the  prevention of the  first and recurrent  stroke, regardless of the  etiology. The basis of secondary  prevention is the  correction of risk factors, as well as the development of an individual program  with antihypertensive, lipid-lowering  therapy. The leading line of secondary  prevention of IS is antiplatelet therapy, which reduces  the risk of developing acute  vascular episodes by 25%. For the purpose  of secondary  prevention of ischemic stroke, acetylsalicylic  acid, dipyridamole, clopidogrel  are used. In the discussed clinical observation, a patient  developed repeated episodes of transient ischemic attack against  the background  of a stenosing  process  in the  common  carotid  artery, hypertension, and a previous  coronavirus  infection. Given that  the  greatest risk of recurrent  stroke is associated with atherosclerosis, which can be complicated by thrombus  formation, chimes and acetylsalicylic acid were chosen for secondary prevention. Follow-up observation showed  the correctness of the chosen tactics.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>цереброваскулярные заболевания</kwd><kwd>ишемический инсульт</kwd><kwd>профилактика</kwd><kwd>дипиридамол</kwd><kwd>COVID-19</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cerebrovascular disease</kwd><kwd>ischemic stroke</kwd><kwd>prevention</kwd><kwd>dipyridamole</kwd><kwd>COVID-19</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Хасанова Д.Р., Данилова В.И. (ред.). Инсульт. Современные подходы диагностики, лечения и профилактики. М.: ГЕОТАР-Медиа; 2019. 352 с. Режим доступа: https://www.rosmedlib.ru/book/ISBN9785970446065.html.</mixed-citation><mixed-citation xml:lang="en">Khasanova D.R., Danilova V.I. (eds.). Stroke. Modern approaches to diagnosis, treatment and prevention. Moscow: GEOTAR-Media; 2019. 359 p. (In Russ.) Available at: https://www.rosmedlib.ru/book/ISBN9785970446065.html.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mao L., Jin H., Wang M., Hu Y., Chen S., He Q. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. https://doi.org/10.1001/jamaneurol.2020.1127.</mixed-citation><mixed-citation xml:lang="en">Mao L., Jin H., Wang M., Hu Y., Chen S., He Q. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. https://doi.org/10.1001/jamaneurol.2020.1127.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chen T., Wu D., Chen H., Yan W., Yang D., Chen G. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;(368):m1091. https://doi.org/10.1136/bmj.m1091.</mixed-citation><mixed-citation xml:lang="en">Chen T., Wu D., Chen H., Yan W., Yang D., Chen G. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;(368):m1091. https://doi.org/10.1136/bmj.m1091.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Belani P., Schefflein J., Kihira S., Rigney B., Delman B.N., Mahmoudi K. et al. COVID-19 Is an Independent Risk Factor for Acute Ischemic Stroke. Am J Neuroradiol. 2020;41(8):1361–1364. https://doi.org/10.3174/ajnr.A6650.</mixed-citation><mixed-citation xml:lang="en">Belani P., Schefflein J., Kihira S., Rigney B., Delman B.N., Mahmoudi K. et al. COVID-19 Is an Independent Risk Factor for Acute Ischemic Stroke. Am J Neuroradiol. 2020;41(8):1361–1364. https://doi.org/10.3174/ajnr.A6650.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cao J., Hu X., Cheng W., Yu L., Tu W.J., Liu Q. Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. Intensive Care Med. 2020;46(5):851–853. https://doi.org/10.1007/s00134-020-05987-7.</mixed-citation><mixed-citation xml:lang="en">Cao J., Hu X., Cheng W., Yu L., Tu W.J., Liu Q. Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. Intensive Care Med. 2020;46(5):851–853. https://doi.org/10.1007/s00134-020-05987-7.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Li M., Wang M., Zhou Y., Chang J., Xian Y. et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020;5(3):279–284. https://doi.org/10.1136/svn-2020-000431.</mixed-citation><mixed-citation xml:lang="en">Li Y., Li M., Wang M., Zhou Y., Chang J., Xian Y. et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020;5(3):279–284. https://doi.org/10.1136/svn-2020-000431.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Umapathi T., Kor A.C., Venketasubramanian N., Lim C.C., Pang B.C., Yeo T.T. et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004;251(10):1227–1231. https://doi.org/10.1007/s00415-004-0519-8.</mixed-citation><mixed-citation xml:lang="en">Umapathi T., Kor A.C., Venketasubramanian N., Lim C.C., Pang B.C., Yeo T.T. et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004;251(10):1227–1231. https://doi.org/10.1007/s00415-004-0519-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3.</mixed-citation><mixed-citation xml:lang="en">Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kelly P.J., Murphy S., Coveney S., Purroy F., Lemmens R., Tsivgoulis G. et al. Antiinflammatory approaches to ischaemic stroke prevention. J Neurol Neurosurg Psychiatry. 2018;89(2):211–218. https://doi.org/10.1136/jnnp-2016-314817.</mixed-citation><mixed-citation xml:lang="en">Kelly P.J., Murphy S., Coveney S., Purroy F., Lemmens R., Tsivgoulis G. et al. Antiinflammatory approaches to ischaemic stroke prevention. J Neurol Neurosurg Psychiatry. 2018;89(2):211–218. https://doi.org/10.1136/jnnp-2016-314817.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Qi X., Keith K.A., Huang J.H. COVID-19 and stroke: A review. Brain Hemorrhages. 2021;2(2):76–83. https://doi.org/10.1016/j.hest.2020.11.001.</mixed-citation><mixed-citation xml:lang="en">Qi X., Keith K.A., Huang J.H. COVID-19 and stroke: A review. Brain Hemorrhages. 2021;2(2):76–83. https://doi.org/10.1016/j.hest.2020.11.001.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Patel A.B., Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence. JAMA. 2020;323(18):1769–1770. https://doi.org/101001/jama20204812.</mixed-citation><mixed-citation xml:lang="en">Patel A.B., Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence. JAMA. 2020;323(18):1769–1770. https://doi.org/101001/jama20204812.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Garkowski A., Zajkowska J., Moniuszko A., Czupryna P., Pancewicz S. Infectious causes of stroke. Lancet Infect Dis. 2015;15(6):632. https://doi.org/10.1016/S1473-3099(15)00020-1.</mixed-citation><mixed-citation xml:lang="en">Garkowski A., Zajkowska J., Moniuszko A., Czupryna P., Pancewicz S. Infectious causes of stroke. Lancet Infect Dis. 2015;15(6):632. https://doi.org/10.1016/S1473-3099(15)00020-1.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Li M., Wang M., Zhou Y., Chang J., Xian Y. et al. Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study. Stroke Vasc Neurol. 2020;5(3):279–284. https://doi.org/10.1136/svn-2020-000431.</mixed-citation><mixed-citation xml:lang="en">Li Y., Li M., Wang M., Zhou Y., Chang J., Xian Y. et al. Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study. Stroke Vasc Neurol. 2020;5(3):279–284. https://doi.org/10.1136/svn-2020-000431.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Valderrama E.V., Humbert K., Lord A., Frontera J., Yaghi S. Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke. Stroke. 2020;51(7):e124-e127. https://doi.org/10.1161/STROKEAHA.120.030153.</mixed-citation><mixed-citation xml:lang="en">Valderrama E.V., Humbert K., Lord A., Frontera J., Yaghi S. Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke. Stroke. 2020;51(7):e124-e127. https://doi.org/10.1161/STROKEAHA.120.030153.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Фонякин А.В., Гераскина Л.А., Максимова М.Ю. Антитромбоцитарная терапия в профилактике инсульта после транзиторной ишемической атаки некардиоэмболического генеза. Неврология, нейропсихиатрия, психосоматика. 2021;13(5):14–19. https://doi.org/10.14412/2074-2711-2021-5-14-19.</mixed-citation><mixed-citation xml:lang="en">Fonyakin A.V., Geraskina L.A., Maksimova M.Yu. Antiplatelet therapy in stroke prevention after non-cardioembolic transient ischemic attack. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):14–19. (In Russ.) https://doi.org/10.14412/2074-2711-2021-5-14-19.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Пилипович А.А. Профилактика повторного ишемического инсульта. Consilium Medicum. 2019;21(9):33–38. https://doi.org/10.26442/20751753.2019.9.190571.</mixed-citation><mixed-citation xml:lang="en">Pilipovich A.A. Recurrent ischemic stroke prevention. Consilium Medicum. 2019;21(9):33–38. (In Russ.) https://doi.org/10.26442/20751753.2019.9.190571.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Парфенов В.А. Вопросы совершенствования ведения пациентов с диагнозом «хроническая ишемия головного мозга». Медицинский совет. 2020;(8):11–17. https://doi.org/10.21518/2079-701X-2020-8-11-17.</mixed-citation><mixed-citation xml:lang="en">Parfenov V.V. Improving the management of patients with a diagnosis of chronic cerebral ischemia. Meditsinskiy Sovet. 2020;(8):11–17. (In Russ.) https://doi.org/10.21518/2079-701X-2020-8-11-17.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Акжигитов Р.Г., Алекян Б.Г., Алферова В.В., Белкин А.А., Беляева И.А., Бойцов С.А. и др. Ишемический инсульт и транзиторная ишемическая атака у взрослых: клинические рекомендации. М.: Министерство здравоохранения Российской Федерации; 2021. 181 с. Режим доступа: https://www.neurology.ru/klinicheskie-rekomendacii-ishemicheskiy-insult-i-tranzitornaya-ishemicheskaya-ataka-u-vzroslyh.</mixed-citation><mixed-citation xml:lang="en">Akzhigitov R.G., Alekyan B.G., Alferova V.V., Belkin A.A., Belyaeva I.A., Boitsov S.A. et al. Ischemic stroke and transient ischemic attack in adults: clinical guidelines. Moscow: Ministry of Health of the Russian Federation; 2021. 181 p. (In Russ.) Available at: https://www.neurology.ru/klinicheskie-rekomendacii-ishemicheskiy-insult-i-tranzitornaya-ishemicheskaya-ataka-u-vzroslyh.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Парфенов В.А. Ведение больного после ишемического инсульта. Российский неврологический журнал. 2020;25(5):51–57. https://doi.org/10.30629/2658-7947-2020-25-5-51-57.</mixed-citation><mixed-citation xml:lang="en">Parfenov V.A. Management of a patient after ischemic stroke. Russian Neurological Journal. 2020;25(5):51–57. (In Russ.) https://doi.org/10.30629/2658-7947-2020-25-5-51-57.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Парфенов В.А., Вербицкая С.В. Профилактика повторного некардиоэмболического ишемического инсульта на основе антитромбоцитарных средств. Атеротромбоз. 2016;(2):89–97. https://doi.org/10.21518/2307-1109-2016-2-89-97.</mixed-citation><mixed-citation xml:lang="en">Parfenov V.A., Verbitskaya S.V. Prevention of recurrent non-cardioembolic ischemic stroke based on antiplatelet agents. Atherothrombosis. 2016;(2):89–97. (In Russ.) https://doi.org/10.21518/2307-1109-2016-2-89-97.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008. Сerebrovasc Dis. 2008;25(5):457–507. https://doi.org/10.1159/000131083.</mixed-citation><mixed-citation xml:lang="en">Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008. Сerebrovasc Dis. 2008;25(5):457–507. https://doi.org/10.1159/000131083.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kernan W.N., Ovbiagele B., Black H.R., Bravata D.M., Chimowitz M.I., Ezekowitz M.D. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236. https://doi.org/10.1161/STR.0000000000000024.</mixed-citation><mixed-citation xml:lang="en">Kernan W.N., Ovbiagele B., Black H.R., Bravata D.M., Chimowitz M.I., Ezekowitz M.D. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236. https://doi.org/10.1161/STR.0000000000000024.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–1912. https://doi.org/10.1016/S0140-6736(06)68845-4.</mixed-citation><mixed-citation xml:lang="en">Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–1912. https://doi.org/10.1016/S0140-6736(06)68845-4.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Wang Y., Zhao X., Liu L., Wang D., Wang C. et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–19. https://doi.org/10.1056/NEJMoa1215340.</mixed-citation><mixed-citation xml:lang="en">Wang Y., Wang Y., Zhao X., Liu L., Wang D., Wang C. et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–19. https://doi.org/10.1056/NEJMoa1215340.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007;6(2):115–24. https://doi.org/10.1016/S1474-4422(06)70685-8.</mixed-citation><mixed-citation xml:lang="en">Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007;6(2):115–24. https://doi.org/10.1016/S1474-4422(06)70685-8.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. https://doi.org/10.1136/bmj.324.7329.71.</mixed-citation><mixed-citation xml:lang="en">Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. https://doi.org/10.1136/bmj.324.7329.71.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
